CMS released a broad-ranging proposed rule for the Medicare Advantage and Part D Programs on Thursday, November 16, 2017. The proposed rule addresses a broad and diverse range of MA and Part D regulatory requirements, affecting not only Medicare Advantage Organizations and Part D Sponsors, but also health care providers, pharmacies, pharmaceutical manufacturers and others.
CMS Releases Broad-Ranging Medicare Advantage and Part D Proposed Rule
Posted In Employee Benefits, Health and Welfare Plans
Tags: 21st Century Cures Act, 42 CFR § 423.505(b)(18), Any Willing Pharmacy provisions, AWP, Centers for Medicare & Medicaid Services (CMS), Comprehensive Addiction and Recovery Act of 2016, Medical Loss Ratios, Medicare Advantage, Medicare marketing guidelines, MLR, Part D AWP, Part D Programs, pharmacy rebates, plan sponsors, Proposed Rule, Section 1860D-4(b)(1)(A) of the Social Security Act, Star Ratings
Ankur J. GoelAnkur J. Goel represents health industry clients in significant compliance, False Claims Act, litigation and regulatory matters. Ankur works with a range of health industry clients. He represents health plans on issues arising under Medicare Advantage, Part D, and health insurance exchanges, as well as health care providers on a variety of complex enforcement, compliance, regulatory and litigation matters. Read Ankur Goel's full bio.
Kate McDonaldKate McDonald represents clients across the healthcare industry on complex regulatory matters and high-stakes mergers and acquisitions, affiliations and other investments. She delivers strategic advice on federal and state laws applicable to health insurers and HMOs, including the downstream implications for their provider organizations and vendors, as well as the reimbursement landscape of federal healthcare programs. Kate serves as partner-in-charge of McDermott’s healthcare practice in Washington, DC. Read Kate McDonald's full bio.
Lauren E. ParisiLauren E. Parisi focuses her practice on health advisory matters. Lauren has provided strategic counseling on federal and state legislation, regulations and sub-regulatory guidance related to the Affordable Care Act. She has experience tracking, analyzing and summarizing new regulatory developments related to federal health care reform. Lauren has also represented various clients in civil litigation, arbitration and government investigations. Read Lauren Parisi's full bio.
Related Posts
- 340B Remedy Rule and Medicare Advantage Rates: Navigating Shifting Payments
- Election 2024: Reproductive Rights in the US
- Webinar Replay: Unpacking the Final Mental Health Parity Regulations
- IRS Announces 2025 Limits for Health Savings Accounts, High-Deductible Health Plans and Excepted Benefit HRAs
- CMS Releases CY 2025 Advance Notice for Medicare Advantage and Part D
BLOG EDITORS
STAY CONNECTED
TOPICS
ARCHIVES
RECENT POSTS
- Post-Election Outlook: Issues to Watch for Pharmacy Industry Stakeholders
- Post-Election Health Policy Priorities
- IRS Issues Proposed Regulations to Ensure Expanded Preventative Care Services Coverage
- Will the Affordable Care Act Survive a Trump Presidency?
- DOJ Proposes Restrictions on Transactions Involving Bulk Sensitive Data, Including Health Data
